Chiron and Roche Bury the Hatchet--for Now
Executive Summary
After years of jousting over Chiron's HCV patents, Chiron and Roche have finally come to an agreement, or at least a partial agreement--with implications for anyone working with HCV and HIV testing. Chiron, in exchange for licensing HCV and HIV to Roche for diagnostic purposes, will receive up to $115 million from Roche, not counting future royalties. But their disagreement over rights to HCV and HIV for blood screening has yet to be resolved.